TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22115340

Group type: EXPERIMENTAL
Intervention: Home-based walking intervention
Number of subjects: 484

Group type: COMPARATOR
Intervention: Health-education waiting list group (control)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Physical performance assessments (subset of participants, n = 194)
Number of subjects: 484
Study: 19793849

Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet + Exercise (LoGI + EX)
Number of subjects: 32

Group type: COMPARATOR
Intervention: High-glycemic index diet + Exercise (HiGI + EX)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (LoGI + EX and HiGI + EX)
Number of subjects: 32
Study: 17101314

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (880 mug, divided twice daily for 3 months)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 36
Study: 15568199

Group type: EXPERIMENTAL
Intervention: Rational mode of processing
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Experiential mode of processing
Number of subjects: 163
Study: 11329400

Group type: EXPERIMENTAL
Intervention: Risperidone (2-6 mg/day, mean modal dose=4.8 mg/day)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Olanzapine (5-20 mg/day, mean modal dose=12.4 mg/day)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 377

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 377
Study: 8970936

Group type: EXPERIMENTAL
Intervention: Thyroxine (8 microg per kilogram of birth weight) administered daily for six weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo administered daily for six weeks
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Thyroxine treatment
Number of subjects: 200
Study: 8215267

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g every 24 h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cefonicid (2 g every 12 h)
Number of subjects: 60
Study: 2442991

Group type: EXPERIMENTAL
Intervention: Nadolol (mean dose 94 mg daily) plus class I antiarrhythmic agents (quinidine or procainamide)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Class I antiarrhythmic agents alone
Number of subjects: 18
Study: 29783983

Group type: EXPERIMENTAL
Intervention: Dietary support (seven sessions with a dietitian)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Social support (befriending) control condition
Number of subjects: 67
Study: 27372221

Group type: EXPERIMENTAL
Intervention: Integrated healthcare model comprising an assigned internist and a hospital liaison nurse
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard care (conventional reactive healthcare system)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Subgroup of patients under 80 years of age with three or more clinical categories
Number of subjects: 140
Study: 25477988

Group type: EXPERIMENTAL
Intervention: Individualized herbal decoction
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control decoction
Number of subjects: 3
Study: 22801400

Group type: EXPERIMENTAL
Intervention: Miller's original vein collar
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: St Mary's boot vein collar
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Vein collar with length/height ratio between 1.18 and 1.63
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Large volume vein collar
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Larger volume and length/height ratio between 1.18 and 1.63
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Larger volume and length/height ratio > 1.63
Number of subjects: 180
Study: 20039197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 163
Study: 18772275

Group type: EXPERIMENTAL
Intervention: Modified total-body recumbent stepper (mTBRS-XT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cycle ergometer exercise protocol
Number of subjects: 11
Study: 15617667

Group type: EXPERIMENTAL
Intervention: EYES condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAR condition
Number of subjects: 0
Study: 12171822

Group type: EXPERIMENTAL
Intervention: MDI/DED (metered-dose inhaler with delivery enhancement device)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Wet nebulization (as a control for teaching)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MDI/DED teaching
Number of subjects: 93

Group type: COMPARATOR
Intervention: Single bronchodilator dose by wet nebulization
Number of subjects: 93
Study: 10483808

Group type: EXPERIMENTAL
Intervention: Concentric contractions training group (n = 12)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untrained control group (n = 8)
Number of subjects: 20
Study: 8583366

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone loading dose of 50 micrograms kg‐1 over 10 min followed by maintenance infusion of 0.45 micrograms kg‐1 min‐1 for moderate renal impairment (n = 10)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone loading dose of 50 micrograms kg‐1 over 10 min followed by maintenance infusion of 0.35 micrograms kg‐1 min‐1 for severe renal impairment (n = 11)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone (both groups)
Number of subjects: 21
Study: 2111933

Group type: EXPERIMENTAL
Intervention: Oral prophylactic penicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7030973

Group type: EXPERIMENTAL
Intervention: Dioxonium (30, 40, and 60 microgram/kg i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pancuronium (0.05 and 0.1 mg/kg i.v.)
Number of subjects: 0
Study: 30855468

Group type: EXPERIMENTAL
Intervention: Supreme group (n=41)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Air-Q SP group (n=43)
Number of subjects: 84
Study: 28062124

Group type: EXPERIMENTAL
Intervention: Text message group (received two messages weekly for four consecutive weeks)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Control group (did not receive text messages)
Number of subjects: 317
Study: 27716184

Group type: EXPERIMENTAL
Intervention: FET-PET guided radiotherapy target volume delineation
Number of subjects: 200

Group type: COMPARATOR
Intervention: T1Gd-MRI guided radiotherapy target volume delineation
Number of subjects: 200
Study: 25726788

Group type: EXPERIMENTAL
Intervention: Adaptol (1000 mg daily for 30 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Noofen (500 mg daily for 30 days)
Number of subjects: 60
Study: 23082447

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 mg weekly for 3 months
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 19572930

Group type: EXPERIMENTAL
Intervention: 1.25 mg/ml ropivacaine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 1.25 mg/ml ropivacaine with 0.2 mcg/kg/h fentanyl
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 1.5 mg/ml ropivacaine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 1.5 mg/ml ropivacaine with 0.2 mcg/kg/h fentanyl
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (1.25 mg/ml ropivacaine)
Number of subjects: 108
Study: 17868242

Group type: EXPERIMENTAL
Intervention: Certified Safe Farm (CSF) intervention including occupational health screenings, health and wellness screening, education, on-farm safety reviews, and performance incentives.
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control cohort (no intervention).
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Certified Safe Farm (CSF) intervention.
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Intervention cohort (safest farms scoring in the highest tertile).
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Intervention cohort (least safe farms scoring in the lowest tertile).
Number of subjects: 316
Study: 16868976

Group type: EXPERIMENTAL
Intervention: Ciclesonide (CIC) 160 microg/day
Number of subjects: 556

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 176 microg/day
Number of subjects: 556
Study: 12534315

Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/day
Number of subjects: 75

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 75
Study: 10649617

Group type: EXPERIMENTAL
Intervention: 3D‐MPL and QS21 with SBAS‐2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3D‐MPL and QS21 with SBAS‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alum
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SBAS‐2 with rgp120W61D
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 8783388

Group type: EXPERIMENTAL
Intervention: GnRH agonist D‐Trp6‐LHRH (Decapeptyl) 3.2 mg for 12 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Human menopausal gonadotropin (Pergonal) for 11 days
Number of subjects: 19
Study: 1902404

Group type: EXPERIMENTAL
Intervention: Intravenous heparin therapy (n = 99)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Aspirin (300 mg/day) and dipyridamole (300 mg/day) (n = 103)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Intravenous heparin therapy
Number of subjects: 241

Group type: COMPARATOR
Intervention: Aspirin and dipyridamole
Number of subjects: 241
Study: 6353879

Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg t.i.d.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg t.i.d.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ketanserin 60 mg t.i.d.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional drugs (previous treatment)
Number of subjects: 31
Study: 31023380

Group type: EXPERIMENTAL
Intervention: Immediate catheter drainage (within 24 h)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Postponed catheter drainage (current standard care)
Number of subjects: 104
Study: 30032443

Group type: EXPERIMENTAL
Intervention: Gynophilus® (Lcr regenerans®) immediate release capsules administered daily for 21 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gynophilus® slow release muco-adhesive tablets administered every 3, 4, or 5 days for 21 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gynophilus® slow release muco-adhesive tablets (administered every 3 or 4 days)
Number of subjects: 0
Study: 27769190

Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention including clinical audits, training of personnel, and decision-support reminders via text messages.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (11 hospitals) with no intervention applied.
Number of subjects: 22
Study: 25154525

Group type: EXPERIMENTAL
Intervention: Targeted health intervention
Number of subjects: 573
Study: 21948211

Group type: EXPERIMENTAL
Intervention: Restricted perioperative intravenous fluid regimen
Number of subjects: 161

Group type: COMPARATOR
Intervention: Standard perioperative intravenous fluid regimen
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 161
Study: 19584979

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/day for 12 weeks
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 264
Study: 17594052

Group type: EXPERIMENTAL
Intervention: High hernia sac ligation and excision (group A, n = 238)
Number of subjects: 477

Group type: COMPARATOR
Intervention: No high hernia sac ligation and excision (group B, n = 239)
Number of subjects: 477
Study: 16324298

Group type: EXPERIMENTAL
Intervention: Enflurane at 1.0 MAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.5 MAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Desflurane at 1.5 MAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enflurane at 0.75 MAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Desflurane at 0.75 MAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.75 MAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All three anesthetics at 1.0 MAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All three anesthetics
Number of subjects: 60
Study: 12048365

Group type: EXPERIMENTAL
Intervention: Standard HIV prevention services including access to free condoms, risk-reduction counseling, and STI therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enrollment in clinical trials offering standard HIV prevention services
Number of subjects: 0
Study: 10459399

Group type: EXPERIMENTAL
Intervention: Full (102-g) 15-amino acid drink
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Quarter-strength (25 g) 15-amino acid drink
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 24
Study: 8665996

Group type: EXPERIMENTAL
Intervention: Felodipine oral treatment for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine clearance (CL)
Number of subjects: 0
Study: 1970957

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.25 to 2 mg/70 kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lormetazepam (0.5 to 4 mg/70 kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Midazolam (1.5 to 12 mg/70 kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Diazepam (4 to 32 mg/70 kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.1, 0.3 and 0.9 mg/70 kg)
Number of subjects: 32
Study: 7004273

Group type: EXPERIMENTAL
Intervention: Diazepam (0.05 mg/kg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: d-tubocurarine (0.05 mg/kg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 61
Study: 31705448

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Sham EA
Number of subjects: 124
Study: 31589302

Group type: EXPERIMENTAL
Intervention: Vibrio parahaemolyticus isolates with pirABVp genes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vibrio parahaemolyticus isolates without pirAVp or pirABVp
Number of subjects: 40
Study: 28934785

Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac joint fusion (SIJF) using triangular titanium implants
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conservative management (CM)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac joint fusion (SIJF)
Number of subjects: 103
Study: 25665520

Group type: EXPERIMENTAL
Intervention: TENS (active TENS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (sham TENS)
Number of subjects: 42
Study: 23864098

Group type: EXPERIMENTAL
Intervention: Tamoxifen, 5 mg/day
Number of subjects: 1884

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1884
Study: 21382868

Group type: EXPERIMENTAL
Intervention: E(dd)→T(dd)→CMF (dose-intensified chemotherapy)
Number of subjects: 733

Group type: COMPARATOR
Intervention: EC→T (standard chemotherapy)
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Darbepoetin
Number of subjects: 733

Group type: COMPARATOR
Intervention: No darbepoetin
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Pathological complete response (pCR)
Number of subjects: 733

Group type: COMPARATOR
Intervention: No pathological complete response (pCR)
Number of subjects: 733
Study: 19995249

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 2.5 mg/ml, 15 ml every three hours for 45 hours
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 17853753

Group type: EXPERIMENTAL
Intervention: Acupuncture at the five-zangshu
Number of subjects: 40

Group type: COMPARATOR
Intervention: Premarin tablets (control)
Number of subjects: 40
Study: 15206671

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 157

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 157
Study: 11486106

Group type: EXPERIMENTAL
Intervention: Prothrombotic disorders detected in patients
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Anticardiolipin/anti‐beta(2)‐glycoprotein I antibodies
Number of subjects: 10
Study: 9722109

Group type: EXPERIMENTAL
Intervention: Equipoise
Number of subjects: 0
Study: 7833657

Group type: EXPERIMENTAL
Intervention: Low dose (30 mCi) radioactive iodine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High dose (50‐250 mCi) radioactive iodine
Number of subjects: 200

Group type: COMPARATOR
Intervention: No postoperative treatment with radioactive iodine
Number of subjects: 200
Study: 3259100

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 20
Study: 31820158

Group type: EXPERIMENTAL
Intervention: Hernia sac transection (TS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Complete sac reduction (RS)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 30921978

Group type: COMPARATOR
Intervention: Radiofrequency thermoablation of the Gasserian ganglion (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermoablation of the peripheral branches of the trigeminal nerve (Study)
Number of subjects: 40
Study: 28949844

Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) results disclosure
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Qualitative interviews regarding WGS results
Number of subjects: 202
Study: 26583660

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LCC)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Conservative watchful waiting (Control)
Number of subjects: 85
Study: 24294742

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate plus Serophene (25 mg vaginally and 100-150 mg orally)
Number of subjects: 42
Study: 21593403

Group type: COMPARATOR
Intervention: KP-1461 (400-3200 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: KP-1461 (3200 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: KP-1461 (1600 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 18284406

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg/day at night
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no phosphodiesterase-5 inhibitors)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Comparison between sildenafil and control group
Number of subjects: 43
Study: 17319450

Group type: EXPERIMENTAL
Intervention: CJC-1008
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 12649818

Group type: EXPERIMENTAL
Intervention: Informal peer group experience
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15125329

Group type: EXPERIMENTAL
Intervention: Combined vaccine (Twinrix: HAV 720 UE/HBV 20 micrograms)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Separate vaccines (Engerix B 20 micrograms/Havrix 720 UE)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Combined vaccine (Twinrix)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Separate vaccines (Engerix B/Havrix)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Combined vaccine (Twinrix) and Separate vaccines (Engerix B/Havrix)
Number of subjects: 73
Study: 10471107

Group type: EXPERIMENTAL
Intervention: 3 h HIV‐STD risk reduction behavioural skills building latex condom intervention
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 3 h skills workshop focused on male polyurethane condoms
Number of subjects: 108

Group type: COMPARATOR
Intervention: 3 h HIV education workshop
Number of subjects: 108
Study: 7641922

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Fallopian sperm perfusion
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with clomiphene citrate (CC)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Fallopian sperm perfusion with clomiphene citrate (CC)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with gonadotropins
Number of subjects: 240

Group type: COMPARATOR
Intervention: Fallopian sperm perfusion with gonadotropins
Number of subjects: 240
Study: 2787664

Group type: EXPERIMENTAL
Intervention: Propofol 2.8 mg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thiopentone 5 mg kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unmedicated controls (neonates delivered by uncomplicated vaginal delivery)
Number of subjects: 40
Study: 59806

Group type: EXPERIMENTAL
Intervention: Nursing intervention (bi-weekly visits for two months)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no intervention after initial setup)
Number of subjects: 9
Study: 31664046

Group type: EXPERIMENTAL
Intervention: Machine learning model based on phase-diagram inspired parameters
Number of subjects: 600
Study: 28414606

Group type: EXPERIMENTAL
Intervention: Topically applied undiluted heterologous serum
Number of subjects: 41

Group type: COMPARATOR
Intervention: Isotonic saline (0.9% NaCl) solution
Number of subjects: 41
Study: 25595580

Group type: EXPERIMENTAL
Intervention: 500 mg intravenous azithromycin, administered 15, 30, or 60 minutes before incision, infused over 1 hour
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 500 mg intravenous azithromycin
Number of subjects: 30
Study: 23334506

Group type: COMPARATOR
Intervention: HEC gel
Number of subjects: 1543

Group type: COMPARATOR
Intervention: No-gel
Number of subjects: 1543
Study: 21342392

Group type: EXPERIMENTAL
Intervention: Multimedia (MM) presentation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Verbal consent
Number of subjects: 61

Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 61
Study: 19760299

Group type: EXPERIMENTAL
Intervention: Linear regression model
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: Probit regression model
Number of subjects: 2003

Group type: COMPARATOR
Intervention: Single predictors (education or poverty alone)
Number of subjects: 2003
Study: 17353316

Group type: EXPERIMENTAL
Intervention: Diffusion and magnetization transfer (MT) techniques in CEC patients
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Diffusion and magnetization transfer (MT) techniques in CD patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 35